---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123703"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:47:54.652497+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Akari shareholders approve Peak Bio merger; close targeted Nov 13, Nasdaq listing risk seen removed

## Summary
- All six merger proposals passed with ~99% of vote; 14.6B shares for Merger Allotment.
- Transaction expected to close on November 13, 2024.
- Upon close, Akari expects to remedy Nasdaq shareholder deficiency, removing delisting risk.
- All-stock merger structured for ~50/50 ownership between Akari and Peak Bio holders.
- Combined entity to operate as Akari Therapeutics, trading as AKTX on Nasdaq.

## SEC filing metadata
- accession: 0000950170-24-123703
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017024123703/0000950170-24-123703-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017024123703/aktx-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123703
- JSON: https://secwatch.observer/filing/0000950170-24-123703.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123703.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.